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LETTERS TO THE EDITORRegarding “Progression of asymptomatic carotid
stenosis despite optimal medical therapy”
Conrad et al1 concluded that optimal medical therapy (OMT)
with carotid revascularization (surgery/endarterectomy), in appro-
priate patients, remains the standard of care. However, ﬂawed con-
clusions may follow from studies with substantial limitations. The
authors retrospectively separated 794 patients with moderate
asymptomatic carotid stenosis (ACS) or recently asymptomatic ca-
rotid stenosis into two groups: 241 “OMT patients” (deﬁned as
taking a statin and aspirin and those who happened to have $1
low-density lipoprotein cholesterol [LDL-C] level that was
always <100 mg/dL) and everyone else (553 “non-OMT/con-
trol” patients). The authors saw no difference in rate of stenosis
progression, ipsilateral neurological symptoms, or survival between
these subgroups and concluded that OMT offered no advantage
(implying no advantage also over the medical therapy received in
long-ago endarterectomy trials in which randomization occurred
from 1983 to 2003). These conclusions are unjustiﬁed because:
(1) The “OMT and non-OMT” subgroups1 were not
clearly distinguished because they received similar med-
ical therapy. Most patients in both groups took aspirin
and a statin, as approximately 87% of the whole cohort
received these. Also, absent LDL-C monitoring does
not mean that blood levels were above target. Labeling
patients without a documented LDL-C level (25% of
their patients) as “non-OMT” was inappropriate,
further limiting subgroup outcome comparisons.
(2) Current OMT was not accurately deﬁned: it is not
simply prescribing any statin at any dose and aspirin
and determining $1 LDL-C level. At the least, it is
optimally identifying all established vascular risk factors
and reducing risk by optimally encouraging a healthy
lifestyle and appropriate medication. Today, 80-90%
of strokes associated with ACS can be prevented
with the use of medical therapy alone.2,3 Stroke risk
falls with the number of risk factors identiﬁed and
treated with the use of medical therapy.4,5 Conrad
et al reported the prevalence of only some established
vascular risk factors in their study and did not describe
the medical treatment for most of these. Furthermore,
an LDL-C target of 70 mg/dL (achieved in only 10%
of their patients) or a 50% LDL-C reduction would be
more appropriate for patients with such a high base-
line prevalence of at least some major risk factors.6-8
Conrad et al emphasized that OMT failed to prevent stenosis
progression or ipsilateral neurological symptoms in 45% of their
cohort at 5 years. However, the aim of surgery for ACS is to prevent
ipsilateral stroke. The average annual rate of ipsilateral stroke was
only approximately 1.3% in the whole cohort and 1.8% for arteries
with progression. Furthermore, these rates may be artiﬁcially
elevated relative to standardized measurements2 (as with the
REACH Registry9) as the result of methodology. For example, it
was not stated by Conrad et al if they included only the ﬁrst ipsilat-
eral neurological symptom per patient in their rates. In addition, sur-
gery could not have prevented most strokes if stenosis progression1752was used as the criteria for surgery because most (60%) ipsilateral
neurological symptoms (including stroke) occurred in those without
progression, as also found in the ACSRS study.10
Subgroups of patients with ACS who now beneﬁt from cur-
rent OMT plus surgery have not been identiﬁed. However, the
overall annual ipsilateral stroke rate for patients with moderate or
severe (60-99%) ACS with current OMT alone will be low
(approximately #0.5-1.0%2,3). Research is required to measure
the impact of current OMT and to determine if we can identify
the small minority of patients who might now beneﬁt from surgery.
Although all patients with ACS should receive current OMT, the
beneﬁt of additional carotid procedures remains to be proven.
Anne Abbott, MBBS, PhD, FRACP
School of Public Health and Preventive Medicine
Monash University
Melbourne, Australia
Preventative Health
Baker IDI Heart and Diabetes Institute
Melbourne, Australia
Stroke Division, Florey Institute of Neuroscience and
Mental Health
Melbourne, Australia
George Geroulakos, MD, FRCS, FRCSE, DIC, PhD
Department of Vascular Surgery
Imperial College
London, United Kingdom
Department of Vascular Surgery
Ealing Hospital
London, United Kingdom
Dimitri P. Mikhailidis, BSc, MSc, MD, FCP, FRSPH, FFPM,
FRCP, FRCPath
University College London Medical School
University College London
London, United Kingdom
Andrew N. Nicolaides, MS, FRCS, PhD (Hon)
Department of Vascular Surgery
Imperial College
London, United Kingdom
Vascular Diagnostic Centre
London, United Kingdom
Henrik Sillesen, MD, DMSc
Department of Vascular Surgery
Rigshospitalet
University of Copenhagen
Copenhagen, Denmark
Frank J. Veith, MD
Division of Vascular Surgery
The Cleveland Clinic
Cleveland, Ohio
Division of Vascular Surgery
New York University Medical Center
New York, NY
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 6 Letters to the Editor 1753REFERENCES
1. Conrad MF, Baloum V, Mukhopadhyay S, Garg A, Patel VI,
Cambria RP. Progression of asymptomatic carotid stenosis despite
optimal medical therapy. J Vasc Surg 2013;58:128-35.
2. Abbott AL. Medical (nonsurgical) intervention alone is now best for
prevention of stroke associated with asymptomatic severe carotid ste-
nosis: results of a systematic review and analysis. Stroke 2009;40:
e573-83.
3. Abbott AL. Stroke rates associated with asymptomatic carotid stenosis
and medical treatment alone continue to fall: results of an updated
meta-analysis (late breaking science abstract presented at the AHA
International Stroke Conference, 2013). Available at: http://my.
americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/
documents/downloadable/ucm_448656.pdf.
4. Amarenco P, Goldstein LB, Messig M, O’Neill BJ, Callahan A 3rd,
Sillesen H, et al. Relative and cumulative effects of lipid and blood
pressure control in the Stroke Prevention by Aggressive Reduction in
Cholesterol Levels trial. Stroke 2009;40:2486-92.
5. Chiuve SE, Rexrode KM, Spiegelman D, Logroscino G, Manson JE,
Rimm EB. Primary prevention of stroke by healthy lifestyle. Circulation
2008;118:947-54.
6. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM,
et al. European guidelines on cardiovascular disease prevention in
clinical practice (version 2012): the ﬁfth joint task force of the Euro-
pean Society of Cardiology and other societies on cardiovascular disease
prevention in clinical practice (constituted by representatives of nine
societies and by invited experts). Atherosclerosis 2012;223:1-68.
7. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT,
Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a
guideline for healthcare professionals from the American Heart Asso-
ciation/American Stroke Association. Stroke 2011;42:517-84.
8. Liapis CD, Bell PF, Mikhailidis DP, Sivenius J, Nicolaides A, Fernandes
e Fernandes J, et al. ESVS guidelines: section a: prevention in patients
with carotid stenosis. Curr Vasc Pharmacol 2010;8:673-81.
9. Aichner FT, Topakian R, Alberts MJ, Bhatt DL, Haring HP,
Hill MD, et al. High cardiovascular event rates in patients with
asymptomatic carotid stenosis: the REACH Registry. Eur J Neurol
2009;16:902-8.
10. Kakkos SK, Nicolaides AN, Charalambous I, Thomas D,
Giannopoulos A, Naylor AR, et al. Predictors and clinical signiﬁcance
of progression or regression of asymptomatic carotid stenosis. J Vasc
Surg 2014;59:956-67.
http://dx.doi.org/10.1016/j.jvs.2014.02.015
Reply
We appreciate our colleagues’ interest in our study. We rather
enjoy the fact that it has raised their collective ire and appreciate
the Journal of Vascular Surgery forum to debunk the myth that
medical therapy will control carotid atherosclerosis. Ours was a
natural history study of patients with asymptomatic moderate
(50%-69%) carotid stenosis who we and everyone else treat
with medical therapy. At no point in the article did we suggest
or recommend that patients with asymptomatic moderate ca-
rotid stenosis undergo any intervention. The authors suggest
that subgroups of patients who would beneﬁt from optimal
medical therapy (OMT) plus surgery for asymptomatic stenosis
have not been identiﬁed. This is, of course, refuted by level 1
evidence,1 and the management strategies embodied in ﬁve
different international guidelines (including that of the Society
for Vascular Surgery [SVS]) published since 2010. Further-
more, the Asymptomatic Carotid Stenosis and Risk of Stroke
(ACSRS) studies, which our correspondents quote and contrib-
uted to, have shown a consistent correlation with the degree of
stenosis and stroke risk.2,3 In ACSRS, patients with an asymp-
tomatic stenosis of a degree wherein surgery would be recom-
mended by current SVS guidelines had a 10% event rate(transient ischemic attack and stroke in approximately a 50/
50 distribution) at just 3 years of follow-up. Ironically, the
most recent ACSRS report further emphasizes the signiﬁcant
impact of lesion progression (the focus of our study) and ﬁnal
degree of stenosis in the prediction of stroke risk.4 In addition,
the 10-year data from the ACST trial showed a signiﬁcant
beneﬁt of carotid endarterectomy over medical therapy despite
an 80% statin use in the later years of the trial.1
The authors began their letter with the statement that “ﬂawed
conclusions may follow from studies with substantial limitations”;
we agree. A good example is the meta-analysis published by Dr
Abbott in 2009, concluding that medical treatment alone is best
for prevention of stroke in patients with asymptomatic severe ca-
rotid stenosis.5 The major ﬂaw of this study was that it did not
differentiate between patients with moderate stenosis (those with
an extremely low stroke risk) and severe stenosis (those who are
at higher risk of stroke with medical therapy alone). The studies
that drive the meta-analysis conclusions included disproportionate
numbers of patients with moderate stenosis. For example, the Ox-
ford Vascular Study reported an annual stroke rate of 0.34% in
medically treated patients with asymptomatic carotid stenosis.6
However, only 32 of the 1152 (2.8%) patients had a degree of ca-
rotid stenosis for which intervention would have been recommen-
ded, and 3 of these (10%) had a stroke.6
It is easy to ﬁnd fault with attempts to deﬁne OMT in medically
treated patients, and we acknowledge the same in our report. Within
the limitations of retrospective review, our study does represent
“real-world” practice in a health system in which, as shown, 87%
of patients in the cohort were taking aspirin and statins. This study
was borne of the rather common observation of lesion progression
in patients receiving adequate, even “optimal”medical therapy. Our
study, in fact, joins many others documenting (1) substantial rates of
carotid lesion progression despite statin therapy and (2) the
ominous implications of lesion progression.4,7-9
The ultimate message of our study was that patients with
asymptomatic moderate carotid stenosis require serial follow-up
imaging despite OMT because a large percentage will progress
to a severe lesion that would ultimately put them at increased
risk of stroke. Our correspondents are understandably uncomfort-
able that data are emerging that refute their “revisionist history”
that medical therapy will control asymptomatic carotid stenosis.
Mark Frederick Conrad, MD, MMSc
Richard P. Cambria, MD
Massachusetts General Hospital
Boston, Mass
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